abstract |
bispecific bcma / cd3 and gprdc5d / cd3 antibodies for use in cancer therapy. the present application concerns bispecific antibodies, bcma * cd3 or grrc5d * cd3. bispecific antibodies should be used in the treatment of refractory cancers, especially after previous treatment with an anti-cd38 antibody. |